​
​

LENZ Therapeutics Stock (NASDAQ:LENZ)

ForecastOwnershipFinancialsChartTranscripts
LENZ Therapeutics by TradingView

Previous Close

$32.92

52W Range

$2.12 - $38.93

50D Avg

$26.27

200D Avg

$18.51

Market Cap

$952.91M

Avg Vol (3M)

$169.25K

Beta

-

Div Yield

$7.21 (20.81%)

LENZ Company Profile

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

-

Employees

-

IPO Date

Mar 22, 2024

Website

-

LENZ Performance

LENZ Financial Summary

Dec 23Dec 22Dec 21
Revenue-$15.00M-
Operating Income$-73.11M$-105.64M$-60.44M
Net Income$-124.65M$-101.05M$-70.76M
EBITDA$-70.70M$-97.29M$-59.71M
Basic EPS$-15.30$-12.89$-8.54
Diluted EPS$-15.30$-12.89$-8.54

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 06, 24 | 11:43 AM
Q2 24Aug 16, 24 | 7:43 PM
Q1 24May 11, 24 | 7:26 AM